Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZJS2E)

Drug Name

4-Amino-3-thiophen-2-yl-butyric acid Drug Info

Synonyms

4-Amino-3-(2-thienyl)butanoic acid; 133933-76-3; CHEMBL315476; 4-amino-3-(thien-2-yl)butanoic acid; 2-Thiophenepropanoicacid, b-(aminomethyl)-; 98593-59-0; 2-BTG; 4-amino-3-thiophen-2-ylbutanoic acid; 4-Amino-3-thiophen-2-yl-butyric acid; beta-(2-Thienyl)-gamma-aminobutyric acid; ACMC-1C0HP; AC1L2ZM2; SCHEMBL341042; CTK4B8884; BDBM50007117; 4-Amino-3-(2-thienyl)butyric acid; 4-amino-3-(2-thienyl) butyric acid; AKOS014313933

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 131689
CAS Number: CAS 98593-59-0
TTD Drug ID: DMZJS2E

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Gamma-aminobutyric acid B receptor (GABBR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[2]
Gamma Hydroxybutyric Acid	DMGBKVD	Narcolepsy	7A20	Approved	[3]
Baclofen	DM0QV1J	Multiple sclerosis	8A40	Approved	[4]
Progabide	DM671NG	Depression	6A70-6A7Z	Approved	[5]
Arbaclofen placarbil	DMO628K	Fragile X syndrome	LD55	Phase 3	[6]
[3H](R)-(-)-baclofen	DMLRHM5	Multiple sclerosis	8A40	Phase 3	[7]
Arabaclofen	DMZB9RI	Fragile X syndrome	LD55	Phase 3	[8]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[1]
SGS742	DM5XYFH	Schizophrenia	6A20	Phase 2	[9]
SSTarbaclofen	DMRGTZ2	Autism spectrum disorder	6A02	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gamma-aminobutyric acid B receptor (GABBR)	TTDCVZW	GABR1_HUMAN; GABR2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
2	Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9.
5	Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav. 1998 Jan;59(1):239-47.
6	Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.J Pharmacol Exp Ther.2009 Sep;330(3):911-21.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242).
8	Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84.
9	SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87.
10	Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128.